Flip flop policy over pioglitazone licence causes media storm in India.
Soumyadeep
S
Bhaumik
D003920:Diabetes Mellitus / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007194:India; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077205:Pioglitazone